Poland· PL-100448536
Ogluo
A glucagon product containing glucagonum, registered in Poland by Tetris Pharma B.V.. The same ATC class is registered in 17 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Glucagon is registered in 17 of 19 countries.
Countries holding a registration under ATC H04AA01 (glucagon), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Glucagon · ATC H04AA01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of glucagon costs, country by country.
Normalised to the WHO defined daily dose (3 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Glucagon · price per daily dose (3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$104.78
The record
At a glance
URPL (Poland)- Active substance
- Glucagonum
- Manufacturer
- Tetris Pharma B.V.
- Country
- Poland (PL)
- ATC code
- H04AA01
- ATC class
- Glucagon
- Defined daily dose
- 3 mg, N
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
22 interactions on record for glucagon.
Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glucagon · interactions on record
22 records
- 1 moderate
- 21 minor
Most severe, free to view
- IndometacinM01AB01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Glucagon in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumOgluo 1 mgStrongbridge Dublin
- United StatesBaqsimiSportpharm LLC
- NetherlandsBaqsimi 3 mg, snuifpoederAmphastar France Pharmaceuticals
- FinlandBaqsimiAmphastar France Pharmaceuticals SAS
- IrelandBaqsimi 3 mg nasal powder in single-dose containerAmphastar France Pharmaceuticals, S.A.S.
- United KingdomGlucaGen Hypokit 1mg powder and solvent for solution for injectionImported
- NorwayBaqsimiAmphastar France Pharmaceuticals
- GermanyGlucagenNovo Nordisk Pharma Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Glucagen, Glucagen Hypokit
- Belgium · Glucagen, Glucagen Hypokit
- Bulgaria · Глюкаген Хипокит
- Cyprus · Glucagen Hypokit
- Czechia · Glucagen Hypokit
- Germany · Glucagen, Glucagen Hypokit
- Denmark · Glucagen, Glucagen Hypokit
- Estonia · Glucagen Hypokit
- Spain · Glucagen Hypokit
- Finland · Glucagen
- France · Glucagen, Glucagen Kit
- Greece · Glucagen, Glucagen Hypokit
- Croatia · Glucagen Hypokit
- Hungary · Glucagen Hypokit
- Ireland · Glucagen Hypokit
- Iceland · Baqsimi, Glucagen
- Italy · Glucagen, Glucagen Hypokit
- Liechtenstein · Baqsimi
- Lithuania · Glucagen Hypokit
- Luxembourg · Glucagen, Glucagen Hypokit
- Latvia · Glucagen Hypokit
- Malta · Glucagen, Glucagen Hypokit
- Netherlands · Glucagen, Hypokit
- Norway · Baqsimi, Glucagon
- Portugal · Glucagen, Glucagen Hypokit
- Romania · Glucagen Hypokit
- Sweden · Glucagon Novo Nordisk
- Slovenia · Glucagen Hypokit
- Slovakia · Glucagen Hypokit
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e88914bd-2c8f-444d-989b-e04eee94e6e8 GET /v1/drugs/e88914bd-2c8f-444d-989b-e04eee94e6e8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": "1 mg",
"packaging": "Rp ¦ EU/1/20/1523/007 ¦ 139402\n1 amp.-strzyk. \nRp ¦ EU/1/20/1523/008 ¦ 139403\n2 amp.-strzyk.",
"substance": "Glucagon hydrochloride 1 mg",
"common_name": "Glucagonum",
"pl_product_id": "100448536",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about glucagon.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.